Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) decreased -4.46% and closed at $37.29 after opening 39.34 with the overall traded volume of 521,940.00 shares. The company’s Market capitalization reached to $1.04 billion, $29.19 million outstanding shares. Its low price was $37.26 and highest price was $39.54. The Distance from 50 day Simple moving average was 36.82% and Distance from 200 day Simple moving average 95.44%.The EPS is -3.17.
Aerie Pharmaceuticals Inc (AERI) reported financial results for the second quarter ended June 30, 2016.
For the second quarter ended June 30, 2016, Aerie reported a net loss attributable to common stockholders, as measured in accordance with U.S. generally accepted accounting principles (“GAAP”), of $23.2 million, or $0.87 per share, compared to $18.8 million and $0.73 per share for the second quarter of 2015. The weighted average number of shares of common stock outstanding utilized in the calculation of net loss per common share was 26,773,337 and 25,841,530 for the second quarters of 2016 and 2015, respectively.
The $23.2 million net loss attributable to common stockholders for the second quarter of 2016 includes $22.7 million in operating expenses, reflecting $13.3 million in research and development expenses and $9.4 million in general and administrative expenses. Excluding $3.9 million of non-cash stock-based compensation expense, adjusted operating expenses for the second quarter of 2016 were $18.8 million, with adjusted research and development expenses of $12.5 million and adjusted general and administrative expenses of $6.3 million. Total adjusted net loss for the second quarter of 2016 was $19.3 million, and adjusted net loss per share was $0.72.
Shares of Heat Biologics Inc (NASDAQ:HTBX) decreased -3.20% and closed at $1.21 after opening 1.26 with the overall traded volume of 523,288.00 shares. The company’s Market capitalization reached to $22.83 billion, $19.49 million outstanding shares. Its low price was $1.16 and highest price was $1.26. The Distance from 50 day Simple moving average was -15.49% and Distance from 200 day Simple moving average was 0.54%. The EPS is -2.05.
Heat Biologics Inc (HTBX) announced that it continues to remain on track to report topline data this quarter from its Phase 2 trials evaluating HS-410 and HS-110 for the treatment of non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC), respectively, as well as its Phase 1b trial evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, Opdivo®, for the treatment of NSCLC.
“We are pleased with the progress we are making and look forward to reporting top-line data in both our NMIBC and NSCLC trials later this quarter,” commented Jeff Wolf, Heat’s Founder and CEO. “We are encouraged by our early data in bladder cancer that suggests we are activating a robust antigen-specific immune response and our data in lung cancer that suggest HS-110 may improve response rates for patients with ‘cold tumors’ who typically have lower response rates to checkpoint inhibitor monotherapy.”